Feasibility study of CBDCA+TS-1 adjuvant therapy for p-stage IB(T2a>4cm)/II/IIIA non-small cell lung cancer
Not Applicable
- Conditions
- non-small cell lung cancer
- Registration Number
- JPRN-UMIN000009101
- Lead Sponsor
- Osaka University Graduate School of Medicine
- Brief Summary
The adjuvant chemotherapy completion rate was 85.3% (29/34); 17/34 (50%) patients completed 4 courses without dose reduction. There were no treatment-related deaths, and Grade 3/4 adverse events included neutropenia (38.2%), leukocytopenia (14.7%), anemia (20.6%), thrombocytopenia (20.6%), anorexia (5.9%), fatigue (5.9%), and oral mucositis (2.9%). Two-year overall and disease-free survival rates were 96.3% and 53.3%, respectively. Adjuvant chemotherapy with carboplatin plus S-1 is safe and feasible.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 35
Inclusion Criteria
Not provided
Exclusion Criteria
Allergy for CBDCA/TS-1 Myocardial infarction within 6 months Interstitial pneumonia sever heart disease significant psychological disease uncontrollable diabetes mellitus
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method